sharetrader
  1. #17001
    Member
    Join Date
    Mar 2014
    Posts
    415

    Default

    Quote Originally Posted by kiwidollabill View Post
    Do you realise that CXbladder is run on Roche Lightcyclers which are basically the non-FDA version of the Cobas.....????

    I'll just leave the rest, its best not to make assessments on 'at first glance....'
    Ok then, Thanks tho, i didn't.

    Ill leave this discussion alone,

  2. #17002
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    21,484

    Default

    Check this out :

    Director, Market Access and Reimbursement
    Pacific Edge Diagnostics USA Ltd.
    Hershey, PA

    Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.

    • Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
    • Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
    • Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
    • Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
    • Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
    • Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
    • Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder
.
    • Developed clinical payer scientific dossier to support coverage of CxBladder.
    • Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
    • Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder



  3. #17003
    Member
    Join Date
    Aug 2017
    Posts
    128

    Default

    Quote Originally Posted by blackcap View Post
    How does getting money for 17k tests make them cashflow positive? lets say $500 per test by my calcs that is $8,500,000. So would still be operating at a loss.
    The reimbursement rate was agreed last October at USD$760 per test

  4. #17004
    Member
    Join Date
    Aug 2017
    Posts
    128

    Default

    Quote Originally Posted by Balance View Post
    Check this out :

    Director, Market Access and Reimbursement
    Pacific Edge Diagnostics USA Ltd.
    Hershey, PA

    Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.

    • Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
    • Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
    • Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
    • Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
    • Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
    • Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
    • Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder
.
    • Developed clinical payer scientific dossier to support coverage of CxBladder.
    • Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
    • Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder



    He left the job 4 years ago

  5. #17005
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    21,484

    Default

    Quote Originally Posted by Nigelk View Post
    He left the job 4 years ago
    Precisely!

    Note the "Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder."

    Looks to me like PEB was rejected for LCD consideration 5 years ago! Was never mentioned once by DD or the company - it was all rah rah rah go go go, remember?
    Last edited by Balance; 21-06-2019 at 05:38 PM.

  6. #17006
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,782

    Default

    "Iterative" was the key word from past company advice.

  7. #17007
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    21,484

    Default

    Quote Originally Posted by Minerbarejet View Post
    "Iterative" was the key word from past company advice.
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

  8. #17008
    Member Drew95's Avatar
    Join Date
    Mar 2019
    Location
    Auckland
    Posts
    99

    Default

    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487

  9. #17009
    Advanced Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    2,019

    Default

    Quote Originally Posted by Drew95 View Post
    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487
    Great show me money and please don’t ask for anymore the dilution is killing shareholders wealth

  10. #17010
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,782

    Default

    Quote Originally Posted by Balance View Post
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

    Why do you think they called it Pacific Edge?

Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •